AstraZeneca PLC mentioned Tuesday that Forxiga has been accredited within the European Union for the remedy of symptomatic persistent coronary heart failure.
The Anglo-Swedish pharma big
AZN,
AZN,
mentioned the approval by the European Commission follows the constructive opinion of the Committee for Medicinal Products for Human Use in December 2022 and was based mostly on outcomes from the Deliver Phase 3 trial.
Heart failure is a persistent, long-term situation that worsens over time and impacts about 15 million individuals in Europe, the corporate mentioned.
Write to Kyle Morris at kyle.morris@dowjones.com
Source web site: www.marketwatch.com
